Karolinska Development Past Earnings Performance
Past criteria checks 0/6
Karolinska Development's earnings have been declining at an average annual rate of -26.2%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been declining at an average rate of 12.9% per year.
Key information
-26.2%
Earnings growth rate
-38.7%
EPS growth rate
Pharmaceuticals Industry Growth | 30.5% |
Revenue growth rate | -12.9% |
Return on equity | -0.5% |
Net Margin | -296.8% |
Next Earnings Update | 15 Nov 2024 |
Recent past performance updates
Recent updates
We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings
May 04Is Karolinska Development (STO:KDEV) Using Too Much Debt?
Aug 19Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year
Apr 27We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings
Feb 08Revenue & Expenses Breakdown
How Karolinska Development makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 2 | -6 | 22 | 0 |
31 Mar 24 | 2 | 34 | 23 | 0 |
31 Dec 23 | 2 | 5 | 22 | 0 |
30 Sep 23 | 2 | 17 | 22 | 0 |
30 Jun 23 | 2 | -41 | 23 | 0 |
31 Mar 23 | 2 | -87 | 23 | 0 |
31 Dec 22 | 2 | -88 | 27 | 0 |
30 Sep 22 | 2 | -118 | 27 | 0 |
30 Jun 22 | 2 | -72 | 28 | 0 |
31 Mar 22 | 2 | 166 | 27 | 0 |
31 Dec 21 | 2 | 171 | 23 | 0 |
30 Sep 21 | 2 | 276 | 21 | 0 |
30 Jun 21 | 2 | 108 | 23 | 0 |
31 Mar 21 | 2 | -106 | 24 | 0 |
31 Dec 20 | 3 | -207 | 24 | 0 |
30 Sep 20 | 3 | 35 | 26 | 0 |
30 Jun 20 | 3 | 190 | 23 | 0 |
31 Mar 20 | 4 | 195 | 24 | 0 |
31 Dec 19 | 3 | 303 | 24 | 0 |
30 Sep 19 | 4 | -11 | 21 | 0 |
30 Jun 19 | 4 | 8 | 20 | 0 |
31 Mar 19 | 3 | 32 | 16 | 0 |
31 Dec 18 | 3 | 31 | 16 | 0 |
30 Sep 18 | 3 | 48 | 20 | 0 |
30 Jun 18 | 3 | 238 | 22 | 0 |
31 Mar 18 | 3 | 185 | 24 | 0 |
31 Dec 17 | 2 | 180 | 25 | 0 |
30 Sep 17 | 5 | 125 | 23 | 0 |
30 Jun 17 | 5 | -87 | 22 | 0 |
31 Mar 17 | 5 | -142 | 20 | 0 |
31 Dec 16 | 5 | -217 | 19 | 0 |
30 Sep 16 | 2 | -315 | 24 | 0 |
30 Jun 16 | 2 | -325 | 25 | 0 |
31 Mar 16 | 3 | -904 | 29 | 0 |
31 Dec 15 | 3 | -1,055 | 33 | 0 |
30 Sep 15 | 4 | -980 | 41 | 0 |
30 Jun 15 | 5 | -1,072 | 51 | 0 |
31 Mar 15 | 5 | -608 | 53 | 0 |
31 Dec 14 | 5 | -371 | 54 | 0 |
30 Sep 14 | 4 | -424 | 47 | 0 |
30 Jun 14 | 5 | -396 | 40 | 0 |
31 Mar 14 | 5 | -169 | 40 | 0 |
31 Dec 13 | 5 | -157 | 40 | 0 |
Quality Earnings: KDEV is currently unprofitable.
Growing Profit Margin: KDEV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KDEV is unprofitable, and losses have increased over the past 5 years at a rate of 26.2% per year.
Accelerating Growth: Unable to compare KDEV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KDEV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.6%).
Return on Equity
High ROE: KDEV has a negative Return on Equity (-0.46%), as it is currently unprofitable.